The future of Medicine will be shaped by the emergence of the next generation of biomedical engineering disciplines that leverage the exponential increase in data and combine it with the computational power to interrogate it, model it, visualize it, built it into machines, and to commercialize it for deployment.
Throughout Mount Sinai, there exist the seeds of a robust biomedical engineering research, design, translation, and entrepreneurship community. To these ends, the Translational and Molecular Imaging Institute (TMII) will be expanded and rebranded into a new BioMedical Engineering and Imaging Institute (BMEII)
BMEII will attracts field-leading faculty, develops unique research and training programs attracting the best medical and graduate students and young innovators, and generate new grants, intellectual property and novel opportunities in entrepreneurship for the Mount Sinai Health System. The BMEII at Mount Sinai is a center of excellence in innovation, training and entrepreneurship in the new fields critical to this transformation of Medicine in addition to the already existing strong imaging and nanomedicine programs within TMII. These new programs will be in: 1) Artificial Intelligence/machine learning (AI/ML); 2) Next generation medical technologies (devices, sensors, and robotics); and 3) Computer vision, virtual and augmented reality.
Research and technology development
at the atomic, molecular, or
RF Coil Lab
The RF Coil Laboratory in BMEII was initially established in 2010. This fully equipped electronics lab is available for RF coil building and troubleshooting.
Developing and using noninvasive imaging methods
that allow the early detection, prevention, and treatment
of cardiovascular disease
Clinical Trials Unit
A modern hybrid between a contract research
organization and an imaging core
Imaging Research Warehouse
A massive image database, developed by
BMEII, is the first of its kind in New York City
Subtle changes in an individual’s heartbeat, which can be measured on an Apple Watch, are able to signal the onset of COVID-19 up to seven days before individuals are diagnosed with the infection. That preliminary observation was made by researchers at the Icahn...
Mount Sinai Hospital opens one of the first centers to study and treat people with what being called “Post-acute COVID Syndrome.”
Please click on the image to watch the 60 Minutes segment. New York, NY (November 22, 2020) — COVID-19 was initially thought to be a disease that was serious for the eldery and people with preexisting conditions. A potentially tough, but temporary respiratory illness...
Nanobiologic immunotherapy uses tiny, bioengineered material to harness immune systemNew York, NY (October 29, 2020) — A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it...
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19
Xueyan Mei, Hao-Chih Lee, […] Yang Yang
Nat Med (2020).
Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging
Max L. Senders, Anu E. Meerwaldt, ... Willem J. M. Mulder
Nat. Nanotechnol. 15, 398–405 (2020).